The idea sounds fantastical: harvest healthy mitochondria from one tissue, isolate them, and inject them into another where existing mitochondria are damaged. But James McCully at Boston Children's Hospital developed the technique for pediatric cardiac surgery: take a biopsy of the patient's healthy skeletal muscle, isolate mitochondria through differential centrifugation, and inject them into damaged myocardium during surgery.

In a series of over 20 pediatric patients with myocardial ischemia-reperfusion injury who were failing to wean from ECMO, autologous mitochondrial transplantation improved ventricular function within 48 hours and allowed ECMO decannulation in approximately 80% of cases. Historical survival was below 30%. Electron microscopy confirmed transplanted mitochondria integrated into cardiomyocytes and formed functional cristae within hours.

The mechanism involves macropinocytosis — a non-specific engulfment process — and tunneling nanotubes that transfer mitochondria directly between cells. Once inside, transplanted mitochondria fuse with the host network through mitofusin-mediated fusion, sharing healthy proteins and mtDNA.

The aging application emerged from a simple observation: aged mitochondria accumulate DNA mutations and deletions, leak more reactive oxygen species, and fragment. Hayashida et al. showed that intravenous injection of young mitochondria into aged mice resulted in uptake in heart, liver, brain, and skeletal muscle. Aged animals showed improved cardiac ejection fraction, reduced hepatic lipid accumulation, and increased muscle ATP. Senescence markers (p16INK4a, p21) were reduced. Effects were transient — lasting 2–4 weeks — suggesting repeated treatments would be needed.

Several companies are advancing the technology. Cellvie is developing standardized isolation and delivery. Mitrix Therapeutics is engineering mitochondria with enhanced uptake by coating them with cell-penetrating peptides. The key challenge is systemic delivery — most injected mitochondria are cleared by liver and spleen before reaching other tissues.

The immunology is surprisingly benign. Despite mitochondria retaining bacterial-like features, autologous transplantation does not provoke immune activation, and even allogeneic transplantation shows minimal rejection, likely because isolated mitochondria lack MHC surface antigens.

The first IND application for mitochondrial transplantation in age-related heart failure is expected in 2027. If successful, it would represent a fundamentally new approach — not a drug, not a gene therapy, but a cellular component transplant.